Impact of inadequately controlled asthma: a need for targeted therapy?
Mehlhop
P D
PD
Brody School of Medicine, East Carolina University, 2495 Henby Lane, Greenville, NC 27834, USA. pmehlkhop@easterncarolinaallergy.com
Blake
K
K
D018927:Anti-Asthmatic Agents / Q000191:economics / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D017281:Cost of Illness; D006296:Health Services / Q000706:statistics & numerical data; D006801:Humans; D007073:Immunoglobulin E / Q000187:drug effects / Q000627:therapeutic use; D000069444:Omalizumab; D015995:Prevalence; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E